Primary liver cancer
Conditions
Interventions
Experimental group:Chemoembolization of hepatic artery with drug-loaded microspheres
Control group:Simultaneous combination of traditional lipiodol chemotherapeutic drug emulsion (C-TACE) and Callispheres drug-loaded microspheres for hepatic artery chemoembolization (DEB-TACE)
Sponsors
Cancer Hospital Affiliated to Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Primary hepatocellular carcinoma confirmed by imaging or pathology; 2. Aged 18-75 year-old patients (both male and female); 3. BCLC stage B; 4. Primary liver cancer unsuitable for surgery or unwilling to undergo surgery; 5. Child-pugh of liver function was grade A; 6. ECOG physical condition score 0-1; 7. The life expectancy of patients is at least 12 weeks; 8. The number of target lesions was less than 3, of which at least one was more than 5 cm in diameter; 9. The patient and/or his family agreed to join the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Malignant tumors in other parts; 2. BCLC was divided into stages 0, A, C and D; 3. Child-Pugh grade B or C of liver function; 4. ECOG physical condition score (>2); 5. Unstable systemic diseases or uncontrolled infections; 6. Pregnant or lactating patients; 7. Chronic renal failure; 8. vascular invasion and extrahepatic metastasis; 9. Any unstable condition that may endanger the patient's safety and his/her compliance with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressive free survival (PFS); | — |
Contacts
Public ContactHe Dongfeng
Cancer Hospital Affiliated to Harbin Medical University
Outcome results
None listed